Free tool
FAERS Monitor: Hympavzi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761369 or its brand name (Hympavzi, Marstacimab-Hncq). Reports on generic versions are filed under their own applications.
Reports
103
Serious
55
53% of reports
Hospitalization
21
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemarthrosis21
- haemorrhage18
- drug dose omission by device9
- device defective7
- device failure6
- epistaxis6
- contusion5
- arthralgia4
- device malfunction4
- drug ineffective4
- joint swelling4
- product dose omission issue4
- transient ischaemic attack4
- traumatic haemorrhage4
- device mechanical issue3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 5 |
| 2025 | 34 |
| 2026 | 64 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemarthrosisSignal | 21 | 479.6 | 327.3 | 9,539 |
| traumatic haemorrhageSignal | 4 | 435.1 | 166.3 | 1,323 |
| device defectiveSignal | 7 | 82.5 | 40.3 | 485 |
| device failureSignal | 6 | 80.5 | 37.0 | 395 |
| device mechanical issueSignal | 3 | 44.7 | 14.7 | 88 |
| haemorrhageSignal | 18 | 35.2 | 23.1 | 567 |
| transient ischaemic attackSignal | 4 | 24.2 | 9.3 | 67 |
| drug dose omission by deviceSignal | 9 | 23.5 | 12.6 | 172 |
| epistaxisSignal | 6 | 16.4 | 7.5 | 72 |
| device malfunctionSignal | 4 | 11.6 | 4.4 | 29 |
| contusionSignal | 5 | 10.6 | 4.5 | 35 |
| joint swellingSignal | 4 | 6.8 | 2.6 | 14 |
| product dose omission issue | 4 | 2.8 | 1.1 | 3 |
| arthralgia | 4 | 2.0 | 0.8 | 1 |
| drug ineffective | 4 | 0.6 | 0.2 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.